Anti-Inflammatory Effects of 0.045% Tazarotene/0.01% Halobetasol Lotion in Psoriasis

• Status: Completed
• Trial end date: 2023-11-13
• Target enrollment: 0
• Participant gender: All

Summary

The objective of this research is to demonstrate superior anti-inflammatory effects, as demonstrated by a reduction in TNF-a and IL-17A, with tazarotene/halobetasol lotion in patients with mild to moderate plaque type psoriasis as compared to clobetasol propionate 0.05% cream.

• Phase: Phase 4
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Dermatology Consulting Services, PLLC
• Treatments: Clobetasol; Halobetasol; Tazarotene

Criteria

Inclusion Criteria:

1. Males or non-pregnant females 18+ years of age.

2. Plaque type mild to moderate psoriasis suitable for topical treatment.

3. The presence of 2 plaques suitable for tape stripping

4. Subjects must be willing to allow a series of tape pieces to be pressed and removed from 2 target psoriasis plaques.

5. Subjects must be in general good health as determined from a medical history.

6. Subjects must read and sign the informed consent form after the nature of the study has been fully explained.

Exclusion Criteria:

1. Subjects with known allergies or sensitivities to ingredients contained in the test products.

2. Subjects with an allergy to latex or adhesives.

3. Subjects with pustular or erythrodermic psoriasis.

4. Subjects who are pregnant or nursing or planning to become pregnant during the course of the study.

5. Subjects who are currently participating in any other clinical study (i.e., dermal patch, use tests, investigational drug or devices, etc.).

6. Subjects viewed by the investigator as not being able to complete the study.

7. Subjects using any type of lotion, medication, or other topical product to the psoriasis plaques.